Durect Corp. and Zogenix Inc. will develop a needle-free formulation of one of the best-selling schizophrenia treatments.
Johnson & Johnson ’s Risperdal Consta requires a large needle for twice-a-month injections into muscle. Cupertino-based Durect and Zogenix, which has research operations in Emeryville, said their Relday would be delivered just under the skin once a month without the use of a needle.
The potential market is big — Risperdal had sales of $1.5 billion last year.
No comments:
Post a Comment